Development of Vancomycin Dose Individualization Strategy by Bayesian Prediction in Patients Receiving Continuous Renal Replacement Therapy
Development of Vancomycin Dose Individualization Strategy by Bayesian Prediction in Patients Receiving Continuous Renal Replacement Therapy
复制标题
DOI：
10.1007/s11095-020-02820-0
复制
发表时间：
2020-05-28
影响因子：
3.7
通讯作者：
Saito, Hideyuki
中科院分区：
文献类型：
--
作者：
Oda, Kazutaka;Jono, Hirofumi;Saito, Hideyuki
目的 在接受连续肾脏替代治疗 (CRRT) 的患者中，万古霉素 (VCM) 浓度通常超出治疗范围 (10-20 μg/ml)。本研究的目的是开发实用的 VCM 群体药代动力学 (PPK) 模型，并评估基于贝叶斯预测的治疗药物监测 (Bayes-TDM) 在接受 CRRT 的患者的 VCM 剂量个体化中的潜力。方法 我们在 17 名接受 CRRT 的患者中使用 80 种治疗浓度开发了 VCM PPK 模型。在 PPK 建模后，对 23 名患者进行了采用 VCM PPK 模型的 Bayes-TDM 评估。结果我们确定了尿量减少的协变量（RUO，
Purpose Vancomycin (VCM) concentration is often out of therapeutic range (10-20 mu g/ml) in patients receiving continuous renal replacement therapy (CRRT). The purposes of this study were to develop a practical VCM population pharmacokinetic (PPK) model and to evaluate the potential of Bayesian prediction-based therapeutic drug monitoring (Bayes-TDM) in VCM dose individualization for patients receiving CRRT. Methods We developed a VCM PPK model using 80 therapeutic concentrations in 17 patients receiving CRRT. Bayes-TDM with the VCM PPK model was evaluated in 23 patients after PPK modeling. Results We identified the covariates reduced urine output (RUO,